Wechselwirkungen · Sivextro
Sivextro 245 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 35
HOS-130291 · Präparat HOS-096879
Adrenergic interactions Two placebo-controlled crossover studies were conducted to assess the potential of 200 mg oral tedizolid phosphate at steady-state to enhance pressor responses to pseudoephedrine and tyramine in healthy individuals. No meaningful changes in blood pressure or heart rate were seen with pseudoephedrine. The median tyramine dose required to cause an increase in systolic blood pressure of ≥ 30 mmHg from pre-dose baseline was 325 mg with tedizolid phosphate compared to 425 mg with placebo. Administration of Sivextro with tyramine-rich foods (i.e., containing tyramine levels of approximately 100 mg) would not be expected to elicit a pressor response.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): placebo (HOS-088378) tyramine (HOS-113328) pseudoephedrine (HOS-113310) tedizolid phosphate (HOS-130230)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-08T12:22:00Z · SHA-256 67755293d17b65838d18c0065efbf6826bb5cdd2698a851f617dd402e701dbd8 · Passage 694ef26d9fc6a158affc4d515322fd5822be1827232828bb3428acfc24e00066 · Zeichen 1868–2543 im Abschnitt